Table 1. Patients characteristics and treatment outcomes.
| Pt nb | Sex | Tumour Type | Indication | Age (year) | Weight (kg) | Previous Lines of Treatment | HD-CT | RX | Previous Treatments Metronomic | Last TTP | Time on treatment | Best Response | Follow-up Weeks | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | Medulloblastoma | PD | 5.5 | 16 | 3 | yes | yes | etoposide | 8 | 8 | PD | 17 | DOD |
| 2 | M | Rhabdoid Renal Tumor | PD | 12 | 23 | 3 | no | yes | etoposide | 6 | 13 | PD | 33 | DOD |
| 3 | M | Medulloblastoma | PD | 9 | 22 | 3 | no | yes | etoposide | 8 | 14 | PD | 52 | AWD |
| 4 | F | Osteosarcoma | M* | 11.5 | 43 | 3 | no | no | no | 6 | 52 | CR | 68 | AWD |
| 5 | M | Neuroblastoma | M | 6 | 20 | 4 | no | yes | COMBAT | 6 | 8 | PD | 12 | DOD |
| 6 | M | Nephroblastoma | M | 12 | 46 | 4 | yes | yes | no | 5 | 14 | PD | 22 | DOD |
| 7 | F | Osteosarcoma | M | 16 | 40 | 3 | no | no | no | 25 | 6 | PD | 14 | DOD |
| 8 | M | RMS | M** | 20 | 54 | 2 | no | yes | nvb-cyclo//tmz | 16 | 52 | CR | 56 | CR |
| 9 | F | Osteosarcoma | M*** | 16 | 52 | 2 | no | no | no | 6 | 24 | CR | 72 | AWD |
| 10 | M | Hodgkin Lymphoma | PD | 18 | 45 | 4 | yes**** | yes | no | ? | 20 | PR | 24 | AWD |
| 11 | M | Glioblastoma | PD | 9.5 | 44 | 3 | no | yes | tmz | 4 | 6 | PD | 6 | DOD |
| 12 | F | Medulloblastoma | PD | 12 | 34 | 3 | no | yes | etoposide | 6 | 6 | PD | 16 | DOD |
| 13 | F | Supratentorial PNET | PD | 11 | 30 | 2 | yes | yes | no | 34 | 14 | PD | 27 | AWD |
| 14 | M | Medulloblastoma | PD | 14 | 24 | 4 | no | yes | no | 32 | 6 | PD | 22 | DOD |
| 15 | M | Osteosarcoma | PD | 10 | 56 | 3 | no | no | no | 12 | 14 | PD | 30 | DOD |
| 16 | M | Osteosarcoma | PD | 8.5 | 27 | 1 | no | no | no | 84 | 24 | PD | 25 | AWD |
SD: Stable Disease; PD: Progressive Disease; AWD: Alive With Disease; DOD: Died Of Disease; M: Maintenance; Nvb: Navelbine; Tmz: Temozolomide; Cyclo: Cyclophosphamide; N.A: Non Available
this patient received zoledronic acid together with the metronomic regimen.
this patient had a primary refractory metastatic osteosarcoma that progressed during the 2 first lines of chemotherapy. Metronomic chemotherapy was proposed as a maintenance therapy after obtaining surgical complete remission of both the primary tumour and bilateral lung metastasis. Monthly zoledronic acid was associated to the metronomic treatment.
this patients had a third metastatic relapse of rhabdomyosarcoma. Metronomic maintenance was proposed after obtaining surgical CR and irradiation of the metastatic site.
this patient was proposed maintenance therapy after obtaining a 3rd surgical complete remission of a metastatic osteosarcoma.
this patient with Hodgkin lymphoma underwent both high dose chemotherapy followed by peripheral blood stem cell transplantation for a relapse and autologous bone marrow transplantation for a subsequent relapse.
The COMBAT protocol is a combination of metronomic etoposide, temzolomide, celecoxib and retinoic acid.
patients with Li Fraumeni syndrom who developed an osteosarcoma as a third tumor.
In children, who received the protocol as maintenance therapy and who were in CR at treatment initiation, the best status was considered as stable disease.